Anemia is complication of Chronic Kidney Disease (CKD) and is associated with significant morbidity and mortality. Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. Literature search was conducted using google scholar, PubMed and scopus until February 2020 to find randomized control trial (RCTs), which assessed Roxadustat on anemia in CKD patients with/without dialysis. Treatment effect were considered as Mean difference and standard deviation (SD) change from the baseline. We performed data analysis using RevMan 5.3. A total of 6 RCTs involving 628 intervention adn 275 control participants were included in the meta analysis. Treatment with Roxadustat significantly raise Hb (0.86, 95% CI, 0,73-0,98; P<0,00001, I= 88%) , TIBC (32.53, 95%CI, 23.56–41.51; P<0.00001, I=96%) and decrease hepcidin level (-31.92, 95% CI, 35.02–28.82; P<0.00001, I=39%) both in dialisis and non dialisis CKD patients compared with control. However, decrease in ferritin level only significant in non-dialisis subgroup (-51.10, 95% CI, 60.82–41.39; P<0.00001, I=55%) and there is no significant change of transferrin saturation in both subgroup. Oral Roxadustat showed efficacy on improving Hb and Iron metabolism in CKD patients both with or without dialysis.